Vertex Pharmaceuticals, Inc, a company of drugs that have recently decided to pursue a vertically integrated business model, decided to build its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will select two drug candidates from their internal research portfolio of four projects to develop on its own, without the help of strategic partners. Director General and CEO Joshua Boger Vicki Sato fight that two projects to choose from. Focuses on how to select the projects and how to manage the portfolio selection. "Hide
by Gary P. Pisano, Lee Fleming, Eli Peter Strick Source: Harvard Business School 24 pages. Publication Date: June 10, 2004. Prod. #: 604101-PDF-ENG
Related Case Solutions & Analyses:
Fishery Products International Ltd.: New Challenge
Martha Stewart Living Omnimedia (A)
Spotfire: Managing a Multinational Start-Up
Farallon Capital Management: Risk Arbitrage (B)
Evolving Role of Semiconductor Consortia in the United States and Japan
Perrier Nestle and the Agnellis
Microsoft South Africa: Corporate Entrepreneurship and Innovation
Dr. Narendran’s Dilemma
InterfaceRAISE: Sustainability Consulting
The U.S. Life Insurance Industry
